Learn more about whether Qiagen N.V. or Stevanato Group S.p.A. is a better investment based on AAII's A+ Investor grades, ...

QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent ...

(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...

The US Food and Drug Administration (FDA) has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic testing offerings in the US.

Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and ...

The Court has denied QIAGEN's Partial Motion to Dismiss and, in the alternative, to stay certain counterclaims brought by Zymo Research, including claims of patent unenforceability and antitrust ...

Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company ...

Qiagen (NYSE:QGEN – Free Report) – Equities researchers at Zacks Research decreased their Q4 2025 earnings per share estimates for Qiagen in a note issued to investors on Wednesday ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Qiagen NV (Symbol: QGEN) entered into oversold territory, hitting an RSI reading of 29.8 ...